The RAS is composed of an enzymatic cascade in which angiotensinogen (AGT) is converted to Angiotensin (Ang) I by renin and subsequently to Ang II by angiotensin-converting-enzyme (ACE). Another important component of RAS, the Ang-(1-7), is primarily formed from Ang II by angiotensin converting enzyme 2 (ACE2). It is well documented that Ang II, acting via its AT1 receptor, is a potent proinflammatory, pro-oxidant, and prothrombotic agent that interferes with several steps of intracellular insulin

signaling. The ACE2/Ang-(1-7)/Mas axis has been suggested as an important counterregulatory arm in the RAS with opposite effects to those of ACE/Ang II/AT1. The Ang-(1-7) can Gefitinib produce NO-dependent vasodilation as well as antiarrhythmic, antiproliferative, and antithrombotic effects [5], [16], [21], [22] and [23]. Recently it was demonstrated that Mas-deficiency in FVB/N mice induces dyslipidemia, lower glucose tolerance and insulin sensitivity, hyperinsulinemia, hyperleptinemia, decreased glucose uptake in white adipose cells, in addition to an increase in adipose tissue mass. On the other hand, transgenic rats with increased circulating Ang-(1-7)

(TGR) have improved lipid and glucose metabolism [22] and [23]. A recent study confirmed the increased Ang-(1-7) plasma levels in TGR (51.82 ± 6.3 in TGR vs. 29.17 ± 8.7 pg/mL in Sprague–Dawley rats); and also showed a lower body weight (278.3 ± 13.3 g in TGR vs. 375.7 ± 10.2 g in Sprague–Dawley rats), improved insulin sensitivity and diminished triglycerides plasma levels (14.82 ± 3.77 mg/dL in TGR vs. 35.22 ± 3.39 mg/dL in Sprague–Dawley rats) in this model CDK activity [23] However, the role of Ang-(1-7) in hepatic gluconeogenesis and glycogenolysis pathways is still poorly understood. Thus, the present study evaluated both pathways in the liver of transgenic rats which express Ang-(1-7) releasing fusion protein

(TGR) showing approximately twofold increase in Ang-(1-7) plasma levels compared to Sprague–Dawley (SD) rats. Ten TGR and control Sprague–Dawley (SD) rats were obtained from the transgenic animal facilities at Laboratory of Hypertension (Federal University Thiamet G of Minas Gerais, Belo Horizonte, Brazil). The animals were kept under controlled light and temperature conditions, with free access to water and chow diet, in accordance to the ethical guidelines of our institution. Rats were sacrificed by decapitation and samples of blood and hepatic tissue were collected, weighed and immediately frozen in dry ice and stored at −80 °C for further analysis. Serum was obtained after centrifugation (3200 rpm for 10 min at 4 °C). ELISA kits were used to measure serum glucagon (ALPCO; Boston, USA) [10]. Hepatic glycogen was extracted and determined as glucose following acid hydrolysis. Briefly, liver samples were placed in tubes with 30% KOH (Sigma; St. Louis, MO, USA) saturated with Na2SO4 (Sigma; St. Louis, MO, USA).